Michel POLAK

Molecular basis of several congenital or neonatal endocrine disorders and establishment of new therapeutic strategies

Published on 22.10.2025

Presentation

Michel POLAK

Contact

The main objective of the group is to understand the molecular basis of several congenital or neonatal endocrine disorders and to establish new therapeutic strategies.

Team

Former Members

Scientific Publications

2025

Digenic Inheritance Mode in Congenital Hypothyroidism Due to Thyroid Dysgenes..., J Clin Endocrinol Metab
2023

Borealin/CDCA8 deficiency alters thyroid development and results in papillary..., Front Endocrinol (Lausanne)
2019

Effectiveness and safety of the tri-iodothyronine analogue Triac in children ..., Lancet Diabetes Endocrinol
2019

Glibenclamide oral suspension: Suitable and effective in patients with neonat..., Pediatr Diabetes
2018

TUBB1 mutations cause thyroid dysgenesis associated with abnormal platelet ph..., EMBO Mol Med
2018

Effectiveness and safety of long-term treatment with sulfonylureas in patient..., Lancet Diabetes Endocrinol
2018

Thyroid Hypoplasia in Congenital Hypothyroidism Associated with Thyroid Perox..., Thyroid
2016

Mutations in BOREALIN cause thyroid dysgenesis., Hum Mol Genet
2016

Update of Thyroid Developmental Genes., Endocrinol Metab Clin North Am
2015

Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patie..., Diabetes Care
2014

RFX6 regulates insulin secretion by modulating Ca2+ homeostasis in human β ce..., Cell Rep
2014

DYRK1A BAC transgenic mouse: a new model of thyroid dysgenesis in Down syndrome., Endocrinology

Faire un don

Michel POLAK

Presentation

Team

Scientific Publications

Digenic Inheritance Mode in Congenital Hypothyroidism Due to Thyroid Dysgenes..., J Clin Endocrinol Metab

Borealin/CDCA8 deficiency alters thyroid development and results in papillary..., Front Endocrinol (Lausanne)

Effectiveness and safety of the tri-iodothyronine analogue Triac in children ..., Lancet Diabetes Endocrinol

Glibenclamide oral suspension: Suitable and effective in patients with neonat..., Pediatr Diabetes

TUBB1 mutations cause thyroid dysgenesis associated with abnormal platelet ph..., EMBO Mol Med

Effectiveness and safety of long-term treatment with sulfonylureas in patient..., Lancet Diabetes Endocrinol

Thyroid Hypoplasia in Congenital Hypothyroidism Associated with Thyroid Perox..., Thyroid

Mutations in BOREALIN cause thyroid dysgenesis., Hum Mol Genet

Update of Thyroid Developmental Genes., Endocrinol Metab Clin North Am

Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patie..., Diabetes Care

RFX6 regulates insulin secretion by modulating Ca2+ homeostasis in human β ce..., Cell Rep

DYRK1A BAC transgenic mouse: a new model of thyroid dysgenesis in Down syndrome., Endocrinology

Funding